Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) Operating Expenses (2016 - 2025)

Veracyte (VCYT) has disclosed Operating Expenses for 14 consecutive years, with $64.8 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 13.14% to $64.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $304.8 million through Dec 2025, up 8.07% year-over-year, with the annual reading at $304.8 million for FY2025, 8.07% up from the prior year.
  • Operating Expenses hit $64.8 million in Q4 2025 for Veracyte, down from $68.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $100.3 million in Q4 2023 to a low of -$35.1 million in Q4 2022.
  • Historically, Operating Expenses has averaged $72.6 million across 5 years, with a median of $76.8 million in 2021.
  • Biggest five-year swings in Operating Expenses: crashed 144.1% in 2022 and later surged 385.43% in 2023.
  • Year by year, Operating Expenses stood at $79.7 million in 2021, then plummeted by 144.1% to -$35.1 million in 2022, then soared by 385.43% to $100.3 million in 2023, then dropped by 25.64% to $74.6 million in 2024, then decreased by 13.14% to $64.8 million in 2025.
  • Business Quant data shows Operating Expenses for VCYT at $64.8 million in Q4 2025, $68.3 million in Q3 2025, and $95.0 million in Q2 2025.